Search
Multiple Myeloma
ALLIANCE A212102 **AT MBMC ONLY** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis**
Blinded Reference Set For Multicancer Early Detection Blood Tests
URCC 19075 **MBMC ONLY**
Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
URCC-21038
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
NCI 10323
Cancer Moonshot Biobank Research Protocol
EAA181
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
URCC 18007
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
S1803 **SUSPENDED** (Upcoming Temporary Suspension 3/29/23 10:00 p.m. cst.)
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
